GEHC vs LNTH vs CBLL Stock Comparison

GE HealthCare Technologies, Lantheus Holdings and Ceribell Prices as of Oct 23, 2026 Peers: Industry group
LNTH Lantheus Holdings, Inc.
$99.80 -0.2% 1M +76.6% 1Y
Market cap
$6.51B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
5 wins
CBLL Ceribell, Inc.
$27.13 +14.9% 1M +109.7% 1Y
Market cap
$1.03B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

10 decided of 12

Lantheus Holdings leads on 5 of the 12 questions below (Lantheus Holdings 5, GE HealthCare Technologies 3, Ceribell 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGEHCLNTHCBLLLeader
Larger companyMarket capitalisation $32.60B $6.51B $1.03B GEHC
Cheaper on earningsLower P/E, profitable companies only 16.4x 23.7x -15.6x GEHC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 14.0x 17.3x — GEHC
Faster revenue growthRevenue growth, trailing twelve months +6.5% +2.3% +31.7% CBLL
More profitableNet margin, trailing twelve months 9.3% 17.7% -64.7% LNTH
Better return on capitalReturn on invested capital 10.1% 12.5% — LNTH
Less leveragedLower net debt / EBITDA 2.4x -0.1x 1.6x LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -7.5% +76.6% +109.7% CBLL
Better 5-year returnAnnualised price return, 5 years — +34.5%/yr — –
Less volatileAnnualised volatility, 1 year 34.9% 32.5% 52.1% LNTH
Higher overall scoreMean of the five percentile scores vs peers 55/100 80/100 38/100 LNTH

Percentile Scorecard

GEHCLNTHCBLL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGEHCLNTHCBLL
Valuation 88 #29 of 228 80 #46 of 228 22 #179 of 228
Growth 22 #173 of 222 62 #84 of 222 20 #177 of 222
Profitability 77 #49 of 210 94 #13 of 210 36 #134 of 210
Financial Health 27 #177 of 241 70 #74 of 241 81 #46 of 241
Shareholder Returns 61 #55 of 138 93 #11 of 138 30 #97 of 138
Overall 55 80 38
  • GEHC ranked among 248 companies in Medical Devices and Diagnostics
  • LNTH ranked among 248 companies in Medical Devices and Diagnostics
  • CBLL ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGEHCLNTHCBLLSPY
1 month +8.1%-0.2%+14.9% -1.0%
3 months +17.9%-4.8%+60.4% +2.9%
6 months +3.8%+18.3%+28.1% +6.4%
Year to date -12.9%+50.0%+23.7% +11.4%
1 year -7.5%+76.6%+109.7% +13.1%
3 years +10.5%+45.7%— +79.4%
3 years, per year +3.4%+13.4%— +21.5%
5 years —+339.3%— +67.7%
5 years, per year —+34.5%— +10.9%
10 years —+1,002.8%— +255.2%
10 years, per year —+27.1%— +13.5%

Risk

MeasureGEHCLNTHCBLLSPY
Volatility, 1Y 34.9%32.5%52.1% 12.7%
Downside volatility, 1Y 36.0%27.5%49.5% 12.7%
Beta vs S&P 500, 1Y 0.670.601.20 1.00
Return / volatility, 1Y -0.222.362.10 1.03
Max drawdown, 5Y -37.4%-59.5%-63.9% -25.4%
From 52-week high -19.0%-10.0%-2.0% -2.5%
52-week high $88.16$110.94$27.68 $779.14
52-week low $59.49$50.69$10.92 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGEHCLNTHCBLL
P/E now vs peer median 16.3xmedian 30.7x 23.6xmedian 30.7x -15.6xmedian 30.7x
P/S now vs peer median 1.5xmedian 3.0x 4.2xmedian 3.0x 10.2xmedian 3.0x
EV/EBITDA now vs peer median 12.0xmedian 17.7x 16.4xmedian 17.7x -13.6xmedian 17.7x
P/FCF now vs peer median 20.4xmedian 23.7x 16.8xmedian 23.7x -19.0xmedian 23.7x
P/B now vs peer median 2.9xmedian 2.4x 5.0xmedian 2.4x 8.1xmedian 2.4x
PEG now vs peer median 2.43median 0.96 0.22median 0.96 —median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGEHCLNTHCBLL
Revenue $21.27B $1.56B $101.96M
Gross profit $8.41B $936.02M $90.65M
Operating income $2.73B $302.34M -$69.97M
Net income $2.05B $275.31M -$66.00M
Free cash flow $1.58B $387.83M -$54.72M
R&D $1.28B $173.09M $22.95M
EPS (diluted) $4.37 $4.08 $-1.74
Cash & equivalents $2.11B $593.30M $32.66M
Total debt $10.09B $571.05M $79.45M
Shares (diluted) 454.00M 67.52M 38.03M
Enterprise value $19.65B $4.68B $429.38M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGEHCLNTHCBLL
P/E 16.3x 23.6x -15.6x
P/FCF 20.4x 16.8x -19.0x
P/Operating cash flow 15.4x 15.8x -19.2x
P/S 1.5x 4.2x 10.2x
P/B 2.9x 5.0x 8.1x
P/Tangible book 3.5x 10.5x 8.1x
EV/EBITDA 12.0x 16.4x -13.6x
EV/EBIT 14.7x 21.5x -13.3x
EV/Revenue 1.9x 4.2x 9.1x
EV/FCF 25.5x 16.7x -17.0x
EV/Operating cash flow 19.2x 15.7x -17.2x
PEG (3Y EPS CAGR) 2.43 0.22 –

Growth

14 metrics
MetricGEHCLNTHCBLL
Revenue growth (1Y) 6.5% 2.3% 31.7%
Revenue CAGR (3Y) 3.8% 11.4% –
Gross profit growth (1Y) 1.3% -3.4% 33.4%
Gross profit CAGR (3Y) 3.7% 16.3% –
Operating income growth (1Y) -0.9% -30.9% -34.6%
Operating income CAGR (3Y) 2.9% 118.8% –
Net income growth (1Y) -11.5% 1.6% -33.6%
Net income CAGR (3Y) 2.9% 102.1% –
EPS growth (1Y) -10.6% 5.8% -27.5%
EPS CAGR (3Y) 6.7% 105.5% –
Operating cash flow growth (1Y) 5.1% -21.7% -44.3%
Operating cash flow CAGR (3Y) 0.2% 14.5% –
Free cash flow growth (1Y) 0.6% -10.1% -41.8%
Free cash flow CAGR (3Y) -2.8% 103.0% –

Profitability

14 metrics
MetricGEHCLNTHCBLL
Gross margin 39.5% 60.1% 88.9%
EBITDA margin 15.7% 25.4% -67.1%
Operating margin 12.9% 19.4% -68.6%
Pretax margin 12.5% 23.3% -64.7%
Net margin 9.3% 17.7% -64.7%
FCF margin 7.4% 24.9% -53.7%
Operating cash flow margin 9.9% 26.5% -53.0%
Return on equity 18.9% 21.8% -49.0%
Return on assets 5.5% 11.6% -38.3%
Return on invested capital 10.1% 12.5% –
Return on capital employed 9.5% 14.8% -45.1%
Asset turnover 0.6x 0.7x 0.6x
Cash conversion (OCF / net income) 1.0x 1.5x 0.8x
Stock comp / revenue 0.7% 5.0% 16.1%

Financial Health

11 metrics
MetricGEHCLNTHCBLL
Debt / assets 27.1% 23.6% 12.0%
Debt / equity 0.9x 0.4x 0.2x
Net debt / EBITDA 2.4x -0.1x 1.6x
Debt / FCF 6.4x 1.5x -0.4x
Liabilities / assets 70.5% 45.7% 22.9%
Equity / assets 29.5% 54.3% 77.1%
Interest coverage 6.4x 15.3x -38.6x
Current ratio 1.3x 3.1x 9.2x
Quick ratio 0.9x 2.8x 8.6x
Cash ratio 0.3x 1.8x 7.5x
Altman Z-score 1.85 5.45 14.41

Shareholder Returns

7 metrics
MetricGEHCLNTHCBLL
Dividend yield 0.3% – –
Net buyback yield 1.2% 2.9% -0.6%
Shareholder yield 1.4% 2.9% -0.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGEHCLNTHCBLL
Forward P/E 14.0xFY2026 17.3xFY2026 –
EPS, next fiscal year $5.09FY2026 $5.76FY2026 $-1.86FY2026
EPS growth, next FY +10.9%FY2026 -5.3%FY2026 –
EPS growth, the year after -0.6% +4.2% –
Revenue, next fiscal year $22.47BFY2026 $1.57BFY2026 $118.32MFY2026
Revenue growth, next FY +8.9%FY2026 +1.8%FY2026 +32.9%FY2026
Revenue growth, the year after +7.5% +12.7% +21.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGEHCLNTHCBLL
Held by institutions 87.0% 100.0% 79.9%
Institutions holding 1,221 465 124
Change in shares held, QoQ +1.7% +3.4% +2.2%
Institutions buying 538 248 74
Institutions selling 461 142 36
Buyers to sellers 1.17 1.75 2.06

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GEHCLNTHCBLL
GEHC 1.00 0.19 0.32
LNTH 0.19 1.00 0.21
CBLL 0.32 0.21 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GEHC, LNTH and CBLL?

GE HealthCare Technologies (GEHC) is the largest by market capitalisation: GE HealthCare Technologies (GEHC) $32.60B, Lantheus Holdings (LNTH) $6.51B, Ceribell (CBLL) $1.03B.

Which stock is cheaper, GEHC, LNTH and CBLL?

GE HealthCare Technologies (GEHC) trades on the lowest price-to-earnings ratio (GE HealthCare Technologies (GEHC) 16.4x, Lantheus Holdings (LNTH) 23.7x, Ceribell (CBLL) -15.6x). On next year's consensus earnings, GE HealthCare Technologies (GEHC) is cheapest (GE HealthCare Technologies (GEHC) 14.0x, Lantheus Holdings (LNTH) 17.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Ceribell (CBLL) grew revenue fastest over the trailing twelve months: GE HealthCare Technologies (GEHC) +6.5%, Lantheus Holdings (LNTH) +2.3%, Ceribell (CBLL) +31.7%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (GE HealthCare Technologies (GEHC) 9.3%, Lantheus Holdings (LNTH) 17.7%, Ceribell (CBLL) -64.7%). On return on invested capital, Lantheus Holdings (LNTH) leads (GE HealthCare Technologies (GEHC) 10.1%, Lantheus Holdings (LNTH) 12.5%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: GE HealthCare Technologies (GEHC) -7.5%, Lantheus Holdings (LNTH) +76.6%, Ceribell (CBLL) +109.7%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (GE HealthCare Technologies (GEHC) 34.9%, Lantheus Holdings (LNTH) 32.5%, Ceribell (CBLL) 52.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GEHC, LNTH and CBLL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.